Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 146.23 Billion KRW | 76.63% |
| 2022 | 82.79 Billion KRW | 23.52% |
| 2021 | 67.02 Billion KRW | 287.66% |
| 2020 | 17.28 Billion KRW | -66.82% |
| 2019 | 52.1 Billion KRW | 52.56% |
| 2018 | 34.15 Billion KRW | -43.48% |
| 2017 | 60.43 Billion KRW | 159.09% |
| 2016 | 23.32 Billion KRW | -84.9% |
| 2015 | 154.44 Billion KRW | 334.94% |
| 2014 | 35.5 Billion KRW | -19.17% |
| 2013 | 43.93 Billion KRW | 94.08% |
| 2012 | 22.63 Billion KRW | 1652.66% |
| 2011 | 1.29 Billion KRW | 110.17% |
| 2010 | -12.69 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 40.27 Billion KRW | -26.78% |
| 2024 Q3 | 34.95 Billion KRW | -23.03% |
| 2024 Q1 | 55 Billion KRW | 59.91% |
| 2023 Q2 | 13.97 Billion KRW | -67.6% |
| 2023 Q3 | 54.7 Billion KRW | 291.35% |
| 2023 Q4 | 34.39 Billion KRW | -37.13% |
| 2023 FY | 146.23 Billion KRW | 76.63% |
| 2023 Q1 | 43.14 Billion KRW | 121.5% |
| 2022 FY | 82.79 Billion KRW | 23.52% |
| 2022 Q4 | 19.48 Billion KRW | -23.23% |
| 2022 Q3 | 25.37 Billion KRW | 37.74% |
| 2022 Q1 | 19.51 Billion KRW | 11.72% |
| 2022 Q2 | 18.42 Billion KRW | -5.6% |
| 2021 Q2 | 7.11 Billion KRW | -62.65% |
| 2021 Q1 | 19.04 Billion KRW | -31.45% |
| 2021 Q4 | 17.46 Billion KRW | -25.35% |
| 2021 Q3 | 23.4 Billion KRW | 229.04% |
| 2021 FY | 67.02 Billion KRW | 287.66% |
| 2020 Q2 | 7.48 Billion KRW | -0.77% |
| 2020 Q3 | -30.84 Billion KRW | -512.22% |
| 2020 Q4 | 27.77 Billion KRW | 190.07% |
| 2020 FY | 17.28 Billion KRW | -66.82% |
| 2020 Q1 | 7.54 Billion KRW | -48.29% |
| 2019 Q2 | 18.34 Billion KRW | 43.92% |
| 2019 Q4 | 14.58 Billion KRW | 126.29% |
| 2019 FY | 52.1 Billion KRW | 52.56% |
| 2019 Q1 | 12.74 Billion KRW | 265.23% |
| 2019 Q3 | 6.44 Billion KRW | -64.86% |
| 2018 Q2 | 13.41 Billion KRW | 75.12% |
| 2018 FY | 34.15 Billion KRW | -43.48% |
| 2018 Q4 | -7.71 Billion KRW | -166.94% |
| 2018 Q3 | 11.52 Billion KRW | -14.15% |
| 2018 Q1 | 7.66 Billion KRW | -8.77% |
| 2017 Q4 | 8.39 Billion KRW | -59.3% |
| 2017 FY | 60.43 Billion KRW | 159.09% |
| 2017 Q2 | 12.46 Billion KRW | -34.12% |
| 2017 Q1 | 18.92 Billion KRW | 147.77% |
| 2017 Q3 | 20.63 Billion KRW | 65.51% |
| 2016 FY | 23.32 Billion KRW | -84.9% |
| 2016 Q1 | 38.07 Billion KRW | -75.79% |
| 2016 Q2 | 20.07 Billion KRW | -47.26% |
| 2016 Q4 | -39.61 Billion KRW | -927.17% |
| 2016 Q3 | 4.78 Billion KRW | -76.15% |
| 2015 Q2 | 11.25 Billion KRW | -11.1% |
| 2015 FY | 154.44 Billion KRW | 334.94% |
| 2015 Q1 | 12.66 Billion KRW | 0.85% |
| 2015 Q4 | 157.24 Billion KRW | 688.49% |
| 2015 Q3 | -26.72 Billion KRW | -337.39% |
| 2014 Q1 | 14.4 Billion KRW | 54.17% |
| 2014 Q4 | 12.55 Billion KRW | 1024.0% |
| 2014 Q3 | 1.11 Billion KRW | -84.96% |
| 2014 FY | 35.5 Billion KRW | -19.17% |
| 2014 Q2 | 7.42 Billion KRW | -48.45% |
| 2013 Q4 | 9.34 Billion KRW | -33.54% |
| 2013 Q1 | 12.47 Billion KRW | 15.06% |
| 2013 Q3 | 14.06 Billion KRW | 74.74% |
| 2013 Q2 | 8.04 Billion KRW | -35.47% |
| 2013 FY | 43.93 Billion KRW | 94.08% |
| 2012 Q4 | 10.84 Billion KRW | 11.69% |
| 2012 FY | 22.63 Billion KRW | 1652.66% |
| 2012 Q2 | 4.71 Billion KRW | 279.57% |
| 2012 Q1 | -2.62 Billion KRW | 0.0% |
| 2012 Q3 | 9.7 Billion KRW | 105.73% |
| 2011 Q3 | -628.85 Million KRW | -232.72% |
| 2011 Q1 | 1.48 Billion KRW | 0.0% |
| 2011 FY | 1.29 Billion KRW | 110.17% |
| 2011 Q2 | 473.82 Million KRW | -68.14% |
| 2011 Q4 | - KRW | 100.0% |
| 2010 FY | -12.69 Billion KRW | 0.0% |
| 2010 Q3 | -5.46 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | 100.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 2136.39% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | -152.168% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 345.409% |
| HANDOK Inc. | -28.79 Billion KRW | 607.792% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 1837.705% |
| Yuhan Corporation | 93.5 Billion KRW | -56.381% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -1214.737% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 689.356% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -4067.783% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 5934.277% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 7150.99% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 3331.744% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -554.783% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 2136.39% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 798.304% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -3980.824% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 223.642% |
| JW Holdings Corporation | 19.02 Billion KRW | -668.575% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 285.271% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 31.192% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -295.152% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 355.09% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -2288.711% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -8690.363% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -2821.85% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 2136.39% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -295.588% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | -31.147% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -295.152% |
| Yuhan Corporation | 93.5 Billion KRW | -56.381% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 999.898% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 3873.178% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -2289.7% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -295.152% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -673.473% |
| Korea United Pharm Inc. | 48.26 Billion KRW | -202.996% |
| CKD Bio Corp. | -24.19 Billion KRW | 704.448% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -511.413% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -432.946% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -391.132% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 355.09% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | -211.081% |
| Boryung Corporation | 40.2 Billion KRW | -263.734% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 566.75% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 5934.277% |
| JW Lifescience Corporation | 28.14 Billion KRW | -419.583% |